Verisante-Retraction of Target Price in Previous Press Release
(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 08/14/13 -- . (TSX VENTURE: VRS)(OTCQX: VRSEF) - Subject to Section 50 (1) (b) of the BC Securities Act, the Company retracts the disclosed target price from the latest press release.
About Verisante Technology, Inc.
committed to . The and the utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.
Verisante Aura™ was awarded Popular Science Magazine's "" for 2011, awarded a for Innovation in Photonics and an for Excellence in Innovation in 2013. Verisante Core™ was named one of the of 2011 by the Canadian Cancer Society.
The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Youtube:
Twitter:
Facebook:
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
Contacts:
Verisante Technology, Inc.
Thomas Braun
President & CEO
(604) 605-0507
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.08.2013 - 14:12 Uhr
Sprache: Deutsch
News-ID 287738
Anzahl Zeichen: 3760
contact information:
Town:
VANCOUVER, BRITISH COLUMBIA
Kategorie:
Hospitals, Facilities and Providers
Diese Pressemitteilung wurde bisher 266 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Verisante-Retraction of Target Price in Previous Press Release"
steht unter der journalistisch-redaktionellen Verantwortung von
Verisante Technology, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
